Barbara Merelli

2.0k total citations
41 papers, 1.1k citations indexed

About

Barbara Merelli is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, Barbara Merelli has authored 41 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 14 papers in Molecular Biology and 8 papers in Epidemiology. Recurrent topics in Barbara Merelli's work include Cancer Immunotherapy and Biomarkers (14 papers), Melanoma and MAPK Pathways (14 papers) and CAR-T cell therapy research (9 papers). Barbara Merelli is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Melanoma and MAPK Pathways (14 papers) and CAR-T cell therapy research (9 papers). Barbara Merelli collaborates with scholars based in Italy, United Kingdom and France. Barbara Merelli's co-authors include Mario Mandalà, Daniela Massi, Laura Cattaneo, Roberto Labianca, Romina Nassini, Gianna Baroni, Eliana Rulli, Alessandra Carobbio, Silvia Deaglio and Valentina Audrito and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Barbara Merelli

38 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Barbara Merelli Italy	18	826	366	313	167	74	41	1.1k
Lucia Festino Italy	18	880 1.1×	375 1.0×	368 1.2×	190 1.1×	69 0.9×	39	1.2k
Vito Vanella Italy	16	709 0.9×	267 0.7×	328 1.0×	145 0.9×	58 0.8×	34	997
Teresa M. Petrella Canada	19	973 1.2×	361 1.0×	390 1.2×	162 1.0×	60 0.8×	62	1.3k
Julie Delyon France	17	649 0.8×	301 0.8×	273 0.9×	130 0.8×	114 1.5×	59	985
Francesco De Rosa Italy	18	694 0.8×	392 1.1×	291 0.9×	168 1.0×	68 0.9×	58	1.1k
Lorenza Di Guardo Italy	15	987 1.2×	398 1.1×	360 1.2×	248 1.5×	75 1.0×	48	1.2k
Suthee Rapisuwon United States	11	683 0.8×	246 0.7×	329 1.1×	158 0.9×	81 1.1×	30	997
Edward F. McClay United States	21	757 0.9×	359 1.0×	403 1.3×	229 1.4×	83 1.1×	57	1.3k
Sangeetha M. Reddy United States	15	499 0.6×	248 0.7×	256 0.8×	139 0.8×	77 1.0×	29	830

Countries citing papers authored by Barbara Merelli

Since Specialization

Citations

This map shows the geographic impact of Barbara Merelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Merelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Merelli more than expected).

Fields of papers citing papers by Barbara Merelli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Merelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Merelli. The network helps show where Barbara Merelli may publish in the future.

Co-authorship network of co-authors of Barbara Merelli

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Merelli. A scholar is included among the top collaborators of Barbara Merelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Merelli. Barbara Merelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ascierto, Paolo A., Michele Del Vecchio, Barbara Merelli, et al.. (2025). 1609P Final, 9-year results from the CheckMate 238 phase III trial of adjuvant nivolumab vs ipilimumab in resected stage IIIB–C or IV melanoma. Annals of Oncology. 36. S887–S888.

Hauschild, Axel, Reinhard Dummer, Mario Santinami, et al.. (2024). Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study.. Journal of Clinical Oncology. 42(16_suppl). 9500–9500. 2 indexed citations

Ascierto, Paolo A., Michele Del Vecchio, Barbara Merelli, et al.. (2023). 1089P Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 7-y results from CheckMate 238. Annals of Oncology. 34. S656–S656. 4 indexed citations

Pinelli, D., et al.. (2023). Pancreatic ductal adenocarcinoma complete regression after preoperative chemotherapy: Surgical results in a small series. Cancer Treatment and Research Communications. 37. 100770–100770. 1 indexed citations

Allievi, Niccolò, Federica Bianco, Michele Pisano, et al.. (2022). Hyperthermic intraperitoneal chemotherapy (HIPEC) as adjuvant and therapeutic options for patients with advanced gastric cancer at high risk of recurrence or established peritoneal metastases: a single-centre experience. Updates in Surgery. 75(1). 159–167. 9 indexed citations

Mandalà, Mario, Piotr Rutkowski, Francesca Galli, et al.. (2022). Acral lentiginous melanoma histotype predicts outcome in clinical stage I-II melanoma patients: an International multicenter study. ESMO Open. 7(3). 100469–100469. 4 indexed citations

Mandalà, Mario, Paul Lorigan, Barbara Merelli, et al.. (2021). SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study. Journal for ImmunoTherapy of Cancer. 9(2). e001694–e001694. 22 indexed citations

Guida, Michele, Sabino Strippoli, Milena Maule, et al.. (2021). Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study. ESMO Open. 6(2). 100064–100064. 35 indexed citations

Rutkowski, Piotr, Alice Indini, Barbara Merelli, et al.. (2020). Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study. Journal for ImmunoTherapy of Cancer. 8(2). e001117–e001117. 39 indexed citations

10.

Zambelli, Alberto, Vittoria Fotia, Paola Poletti, et al.. (2020). 1676MO Prevalence and clinical impact of asymptomatic or mildly symptomatic SARSCoV-2 infection among actively treated cancer patients during COVID-19 pandemic in Italy. Annals of Oncology. 31. S994–S994. 5 indexed citations

11.

Consoli, Francesca, Melissa Bersanelli, Gianluca Perego, et al.. (2019). Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma. Clinical & Translational Oncology. 22(6). 900–907. 8 indexed citations

12.

Schadendorf, Dirk, Anna Maria Di Giacomo, Lev Demidov, et al.. (2019). Health-related quality of life in patients with fully resected BRAFV600 mutation–positive melanoma receiving adjuvant vemurafenib. European Journal of Cancer. 123. 155–161. 3 indexed citations

13.

Massi, Daniela, Emanuela Romano, Eliana Rulli, et al.. (2017). Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients. European Journal of Cancer. 78. 70–81. 33 indexed citations

14.

Mandalà, Mario, Francesco De Logu, Barbara Merelli, Romina Nassini, & Daniela Massi. (2016). Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation. Laboratory Investigation. 97(2). 166–175. 39 indexed citations

15.

Massi, Daniela, Davide Brusa, Barbara Merelli, et al.. (2014). PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Annals of Oncology. 25(12). 2433–2442. 129 indexed citations

16.

Chiarion‐Sileni, Vanna, Jacopo Pigozzo, Paolo A. Ascierto, et al.. (2014). Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. Journal of Experimental & Clinical Cancer Research. 33(1). 30–30. 86 indexed citations

17.

Mandalà, Mario, S. Fagiuoli, Daniela Francisci, et al.. (2013). Hepatitis B in immunosuppressed cancer patients: Pathogenesis, incidence and prophylaxis. Critical Reviews in Oncology/Hematology. 87(1). 12–27. 14 indexed citations

18.

Merelli, Barbara, Daniela Massi, Laura Cattaneo, & Mario Mandalà. (2013). Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities. Critical Reviews in Oncology/Hematology. 89(1). 140–165. 137 indexed citations

19.

Labianca, Roberto, Barbara Merelli, & Stefania Mosconi. (2012). Treatment of advanced pancreatic cancer. Annals of Oncology. 23. x139–x140. 6 indexed citations

20.

Labianca, Roberto & Barbara Merelli. (2011). Screening and diagnosis for colorectal cancer: present and future.. PubMed. 96(6). 889–901. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact